SWOG clinical trial number
SWOG-8594
A Phase III Trial of Cisplatin Alone or in Combination with Doxorubicin, Vinblastine and Methotrexate in Advanced Bladder Cancer
Closed
Phase
Published
Abbreviated Title
A Phase III Trial of Cisplatin Alone or in Combination with Doxorubicin, Vinblastine and Methotrexate in Advanced Bladder Cancer
Activated
10/01/1984
Closed
05/15/1989
Research committees
Genitourinary Cancer
Publication Information Expand/Collapse
1997
Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study.
1992
A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A Cooperative Group Study.
1990
Advanced bladder cancer: A prospective intergroup trial comparing single agent cisplatin (CDDP) vs. M-VAC combination therapy (INT-0078).
Other Clinical Trials
SWOG Clinical Trial Number
S2312
A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature
Research Committee(s)
Genitourinary Cancer
Activated
09/03/2024
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
S2210
S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"
Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
7%
Open
Phase
SWOG Clinical Trial Number
S2200
S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
Accrual
14%
Open
Phase